Tirzepatide (LY3298176): Dual GIP/GLP-1 Agonist Structure and the Trial Record

Evidence at a glance

Phase 3 trials, approved drug

Tirzepatide has the largest human evidence base of any compound covered here, including a head to head Phase 3 trial against semaglutide.

Why researchers are interested

It adds GIP activity to GLP-1. The GIP component appears to improve both the size of the effect and how well the drug is tolerated compared with acting on GLP-1 alone, which is why a dual agonist beat a single one in a direct comparison.

What the research found

• Beat semaglutide head to headGreater HbA1c reduction than semaglutide in a direct Phase 3 comparison (SURPASS-2, Frías, NEJM)
• Large weight reductionSignificant weight loss in adults with type 2 diabetes (SURMOUNT-2, Lancet 2023)
• Better metabolic markersImprovements in lipid profile and blood pressure reported alongside the primary endpoints

Reported in the literature

• Nausea, diarrhoea, vomiting, constipation and reduced appetite are the most frequently reported effects.
• Hypoglycaemia risk rises when it is combined with a sulfonylurea or insulin.
• It carries a boxed warning for thyroid C-cell tumours seen in rodents. Relevance to humans is not established.
• Pancreatitis, gallbladder disease and acute kidney injury are recognised label warnings.

Findings are summarised from the sources listed under References on this page, and from approved product labelling where a compound has one. These are outcomes observed in published studies, not effects claimed for any person, and nothing here is a recommendation for human use.

← All research guides

Tirzepatide (developmental code LY3298176) is a synthetic peptide engineered to activate two incretin receptors with a single molecule. This guide covers its identity and structure, where it sits among incretin compounds, what the published trial record contains, and the distinction between the approved medicine and research material. It is written for researchers and is not medical guidance.

What tirzepatide is

Tirzepatide is a synthetic 39-amino-acid peptide designed as a dual agonist at the GIP receptor and the GLP-1 receptor.

• CAS 2023788-19-2 (PubChem CID 166567236)
• Molecular formula C₂₂₅H₃₄₈N₄₈O₆₈
• Molar mass 4813 g/mol
• Length 39 residues

Verified against PubChem on 2 October 2026.

Two structural features define it. The backbone is built on the GIP sequence rather than the GLP-1 sequence, which is unusual — most incretin compounds start from GLP-1. And it carries a fatty di-acid moiety, a lipid chain that promotes binding to serum albumin and substantially extends how long the molecule persists in circulation. That modification substantially extends the molecule’s circulating half-life relative to an unmodified peptide, and it is a design pattern now common across long-acting peptides.

Research-use note: the active compound has been approved by regulators as a prescription medicine, but the material supplied here is not that pharmaceutical product. It is supplied strictly for laboratory research, is not a supplement, and is not for human or animal consumption. Nothing below describes or endorses use in people.

Where it sits among incretin compounds

These compounds are most clearly placed by counting the receptors each one engages, because that is the structural axis the literature is organised around.

• Single agonist — GLP-1 receptor only. The earliest and largest body of incretin work.
• Dual agonist — GIP + GLP-1. Tirzepatide.
• Triple agonist — GIP + GLP-1 + glucagon. See our retatrutide research guide.

Adding the GIP receptor to GLP-1 activity is what distinguishes tirzepatide from the single-agonist class. A head-to-head comparison with the triple agonist is covered in Tirzepatide vs Retatrutide.

The mechanism as characterised in the literature

Tirzepatide is described as a dual GIP and GLP-1 receptor agonist. Research has examined how simultaneous activation of both incretin pathways relates to insulin secretion, insulin sensitivity and body-weight regulation in study models, investigated as potentially different from activation of the GLP-1 receptor alone. Nauck and D’Alessio (Cardiovascular Diabetology, 2022) review that pharmacology.

For laboratory purposes the consequence is that tirzepatide is not interchangeable with a GLP-1-only comparator. An experiment comparing the two is comparing two receptor profiles, not two strengths of the same thing.

What the published trial record contains

Unusually for a research-market peptide, most of the tirzepatide literature is large registrational clinical-trial data rather than scattered preclinical work.

• Frías et al. (New England Journal of Medicine, 2021) — SURPASS-2, comparing tirzepatide with semaglutide on glycaemic endpoints in type 2 diabetes.
• Garvey et al. (The Lancet, 2023) — SURMOUNT-2, a phase 3 trial examining body-weight endpoints in participants with type 2 diabetes.
• Nauck and D’Alessio (Cardiovascular Diabetology, 2022) — a review of the dual co-agonist pharmacology.

These findings belong to the published research record for the approved medicine. They are not claims about the research compound supplied here, and they are not validated uses of it. Anyone citing them should read the originals: trial endpoints are specific, and secondary summaries in this subject area routinely generalise beyond what was measured.

Form, reconstitution and storage

Tirzepatide is supplied as a lyophilized powder for research use. Standard laboratory practice is to reconstitute with bacteriostatic water, swirl rather than shake until dissolved, and store the reconstituted solution refrigerated at 2–8 °C. The lyophilized powder is kept frozen and protected from light, and repeated freeze-thaw cycles are avoided. Our walkthrough covers the general procedure: how to reconstitute peptides.

(General lab-handling notes, not usage instructions, and no substitute for the protocol in force in the receiving laboratory.)

For research use only

All products and information referenced here are intended strictly for laboratory and scientific research use only. They are not for human or animal consumption and are not drugs, foods, supplements, or medical devices. The research material supplied here is not the approved pharmaceutical product. Nothing here should be interpreted as medical advice. Products are supplied against a stated purity specification.

Explore tirzepatide and related research peptides

• Tirzepatide 20 mg — specifications and stated purity
• Retatrutide (GLP-3) — the GIP/GLP-1/glucagon triple agonist
• Bacteriostatic Water 30 mL — reconstitution diluent
• Full research catalog

Common questions about Tirzepatide

How is tirzepatide different from semaglutide?

Semaglutide acts on the GLP-1 receptor only. Tirzepatide acts on both the GIP and GLP-1 receptors, and the two were compared head to head in the SURPASS-2 trial (Frías et al., NEJM, 2021).

Is research-grade tirzepatide the prescription medicine?

No. It is the same compound (LY3298176), but the material sold here is supplied for laboratory research only. It is not the pharmaceutical product and is not for human use.

How does tirzepatide compare with retatrutide?

Retatrutide adds glucagon-receptor activity to the two receptors tirzepatide targets. See the side-by-side comparison.

References

1. Frías JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021. PubMed
2. Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a phase 3 trial. Lancet. 2023. PubMed
3. Nauck MA, D’Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes. Cardiovasc Diabetol. 2022. PubMed
4. Compound identity verified against the PubChem database, retrieved 2 October 2026. PubChem